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ABSTRACT
Background: Children infected with HIV are at risk 
of developing tuberculosis (TB). Antiretroviral 
therapy has been linked to improved immune 
responses to TB. The objectives of the study were to 
determine the magnitude and quality of immune 
reconstitution in HIV-infected children receiving 
antiretroviral therapy (ART) and to determine 
pathogen-specific immune reconstitution to 
Mycobacterium tuberculosis. 
Methods: A total of 59 children of age 9 months to 5 
years initiating ART with a history of BCG 
vaccination from Matero Reference Clinic in 
Lusaka were enrolled in a prospective cohort study. 
Demographic and clinical data were collected using 
questionnaires. Blood samples were drawn before 
starting ART, at 3 months and 6 months for 
measurement of T cell subsets and PPD stimulation 
for intracellular cytokine staining. 
Results: After 6 months of ART, the median CD4 T 
cell percentage increased from 9.4% at baseline to 
25.9% (p< 0.001). Total CD8 T cell percentage 
decreased from 42.8% pre-ART to 36.5% after 6 
months of ART (p = 0.010). However, naïve CD8 T 
cells increased within the same period (p = 0.038). 
Both activated CD4 and CD8 T cells decreased after 
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6 months of ART (p < 0.001). On the other hand, both 
central memory CD4 and CD8 T cells increased after 
6 months of ART (p = 0.029 and 0.021, respectively), 
while effector memory CD8 T cells decreased (p = 
0.006). After 3 months of ART, CD4 T cells 
expressing IFN-ã decreased (p = 0.033) but after 6 
months of ART the percentage increased to pre-ART 
levels.  
Conclusion:  ART has a positive impact on HIV-
infected children, likely reducing the risk of 
tuberculosis as evidenced by the increases in CD4 T 
cells critical to an effective immune response against 
TB. Before starting ART, anti-mycobacterial 
immune responses seem to be primarily driven by 
effector memory T cells while after ART by central 
memory T cells. Therefore, central memory T cells 
appear to be the primary cells in restoring specific 
immune responses. These findings have valuable 
implications for TB vaccine development strategies 
in HIV-infected children. 
INTRODUCTION
With the scaling up of antiretroviral therapy (ART) 
in sub-Saharan Africa and Zambia in particular, 
more HIV infected children will have access to 
1
treatment . An estimated 250,000 children died of 
AIDS in 2005 and 2.3 million children were 
estimated to be living with HIV/AIDS globally. 
2
Almost 90% of these children live in sub-Sahara . In 
HIV infected children, the risk of developing 
3,4,5tuberculosis (TB) is high .  Over 250,000 children 
develop TB and 100,000 children will continue to 
3
die each year from TB . However, effective therapy 
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should result in improved immune responses to 
6opportunistic infections such as TB . Globally the 
number of children receiving ART increased from 
7about 75,000 in 2005 to almost 200,000 in 2007 . In 
Zambia, out of the estimated 34,000 children in need 
2
of ART 18,040 were receiving ART by 2008 .  
9According to a study by Chintu et al , the 
seroprevalence of HIV-1 in 237 hospitalised 
children aged 1 month to 14 years with clinical 
diagnosis of TB was 37% while it was 10.7% among 
the control group (242 children). Although there 
have been studies in adults suggesting that ART can 
prevent the development of tuberculosis in HIV-
infected individuals, the mechanism is not fully 
understood and very little information exists in 
children . Studies that have focused on the quality of 
immune reconstitution in HIV-infected children who 
are on ART with respect to immunity against TB are 
limited. Previous studies in Belgium have shown 
that upon immune reconstitution, there is an increase 
10,11
in the naïve T cell count in children . However, no 
studies have documented naïve T cells, activated T 




This was a prospective cohort study focusing on 
antimycobacterial immune responses in HIV-
infected children initiating ART.
Study setting and population
The study participants were recruited from Matero 
Reference Clinic in Lusaka, Zambia. The 
Biomedical Research Ethics Committee of the 
University of Zambia granted ethical approval for 
the study. Children 9 months to 5 years of age 
initiating ART with a history of BCG vaccination 
were eligible for analysis. Informed consent was 
obtained from parents or guardians and 
confidentiality was assured and maintained at all 
times. All the laboratory tests were done at the 
Virology Laboratory at the University Teaching 
Hospital. Blood samples were collected before 
starting ART (pre-ART), after 3 months and after 6 
months of ART for enumeration of T-cell subsets 
and intracellular cytokine stimulation and staining. 
Laboratory Investigations
General markers of immune reconstitution
  CD4 and CD8 T cell percentages were obtained 
using Becton Deckinson (BD) monoclonal 
antibodies to CD4, CD8 and CD3. T cell activation 
+ + 
markers CD38 / HLA-DR were used to identify 
+ activated T cells. For naïve T cells CD45RA / 
+  - 
CCR7 , for central memory T cells CD45RA / 
+ - 
CCR7  while for effector memory T cells CD45RA / 
-  CCR7 monoclonal antibodies were used.  
Acquisition was done using a 4- color BD 
FACSCalibur with CellQuest Pro software and then 
analysed FACS plots with FlowJo version7.5.
Mycobacterial specific immune responses
Overnight antigen stimulation: Cells were 
stimulated with tuberculin purified protein 
derivative (PPD; Statens Serum Institute, 
Denmark). Stimulation with Staphylococcal 
enterotoxin B (SEB; Sigma-Aldrich, UK) was done 
as positive control while the negative control was 
left unstimulated. The mixture of cells and antigens 
was incubated overnight at 37°C (16 hours). 
Intracellular cytokine staining: After overnight 
stimulation, cell surface staining using monoclonal 
antibodies for CD3, and CD4 or CD8 (BD 
Pharmingen) was done. This was followed by 
intracellular cytokine staining with IFN-ã 
monoclonal antibodies (BD Pharmingen). 
Acquisition was done using the BD FACSCalibur.
  
Statistical analysis
Data were analyzed using Statistical Package for 
Social Sciences (SPSS) version 18. Wilcoxon 
signed rank test was used to test for significance 
differences between paired data. The median 
percentage and interquartile range (IQR) were 
computed for T cell subsets. A p value of <0.05 was 
considered statistically significant.
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RESULTS
Participation and distribution
A total of 59 children were enrolled in the study, 2 
withdrew, 3 were lost to follow-up and 13 died 
before review at 3 months. This left us with a total of 
41 children.  Out of 41 children who participated in 
the study, 21 (51%) were males while 20 (49%) were 
females. The median age for the males was 23 (Q = 1
19, Q = 32) months while for the females it was 3
21(Q = 16, Q =34) months.  The median age for all 1 3
the children was 22 (Q = 15, Q = 33) months. 1 3
CD4 and CD8 T cell median percentages before 
and after ART 
There was a statistically significant increase in CD4 
T cell percentage from pre-ART (9.4%) to 3 months 
(19.4%; p<0.001) and 6 months (25.9%; p<0.001). 
On the other hand, there was a significant decrease in 
CD8 T cell percentage from pre-ART (42.8%) to 3 
months (38.1%; p=0.026) and 6 months on ART 
(36.5%; p=0.01), (Figure 1A).
Naïve CD4 and CD8 T cell median percentages 
before and after ART
Naive CD4 T cell percentages from pre-ART to 3 
months and 6 months were 21.0%, 21.0% and 
24.0%, respectively (Figure 1B).Naïve CD8 T cell 
percentages for per-ART, 3 months and 6 months 
were 3.5%, 5.7% and 9.5%, respectively. This was a 
statistically significant difference in naïve CD8 T 
cell percentage between per ART and 3 months after 
ART (p=0.048) and between pre- ART and 6 months 
after ART (p=0.038). 
Activated CD4 and CD8 T cell median 
percentages before and after ART
Activated CD4 T cell percentages decreased 
significantly from pre-ART (14.8%) to 3 months 
(9.6%; p<0.001) and 6 months (7.1%; p<0.001). 
Similarly, there was a decrease in the activated CD8 
T cell percentage from pre-ART (37.9%) to 3 
months (24.0%; p<0.001) and 6 months (22.2%; 
p<0.001), (Figure 1C).
Central memory CD4 and CD8 T cell median 
percentages before and after ART
Central memory CD4 T cell percentages for pre-
ART, 3 months and 6 months were 3.2%, 3.4% and 
4.7%, respectively. There was no statistically 
significant difference in central memory CD4 T cell 
percentage between pre-ART and 3 months (p = 
0.179). However, there was a significant difference 
in central memory CD4 T cell percentages between 
pre-ART and 6 months (p = 0.029).  
Conversely, central memory CD8 T cell percentages 
were significantly different at both 3 months (0.12%; 
p=0.020) and 6 months (0.15%, p=0.021) when 
compared to pre-ART (0.05%), (Table 1). 
Effector memory CD4 and CD8 T cell median 
percentages before and after ART
Effector memory CD4 T cell percentages for pre-
ART, 3 months and 6 months were 32.0%, 28.6% 
and 28.4%, respectively. There was no significant 
difference in effector memory CD4 T cell percentage 
at either time point after ART (p = 0.694 for pre ART 
vs. 3 months and p = 0.793 pre ART vs. 6 months). 
 There was a significant decrease in effector memory 
CD8 T cell percentage from pre-ART (39.1%) to 3 
months (24.0%; p<0.001) and 6 months (23.7%; 
p=0.006), (Table 1).
CD4 and CD8 T cells expressing IFNã before and 
after ART 
The CD4 T cell percentage that expressed IFN-ã for 
pre-ART, 3 months and 6 months after ART were 
1.1%, 0.7% and 1.1%, respectively. There was a 
significant difference from pre-ART to 3 months (p = 
0.033), but the percentage at 6 months returned to 
pre-ART levels (Figure 1D).  
Similarly, the percentages of CD8 T cells expressing 
IFN-ã at pre-ART, 3 months and 6 months were 
0.8%, 1.1% and 0.8%, respectively. There were no 
statistically significant differences at either time 
point after ART compared to pre-ART (p = 0.355 for 
pre ART vs. 3months).
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A illustrates the increase in CD4 T cells with a 
conversary decrease in CD8 T cells as the immunity 
builds up after starting ART. B shows increase in 
naïve T cells while C illustrates the reduction in 
activated T cells. D shows specific immune 
response after stimulation with PPD at each time 
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point. CD4 T cells expressing IFN-ã after 3 months 
of ART decreased significantly while at 6 months 
reverted to pre-ART levels. Although there seem to 
be no difference in T cells expressing IFN-ã 
between pre-ART and 6 months, results suggest that 
the primary T cell subsets driving the response at 
these time points are different.
Table 1:  Median percentage of T-cell subsets for pre-ART, 3 months and 6 months on ART  
CM CD4% = Central memory CD4 T Cells 
CM CD8% = Central memory CD8 T Cells
EM CD4% = Effector memory CD4 T Cells 
EM CD8% = Effector memory CD8 T Cells
IQR = Interquartile range
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Table 2:  Median percentage of T-cells expressing INFã after 
stimulation with PPD
T Cells  INFã CD4%  INFã CD8%
Pre-ART  1.1                                
(IQR, 0.5-1.7)  
0.8                                 
(IQR, 0.4-1.3)
3 months 
on ART  
0.7                                
(IQR, 0.3-1.2)  





1.1                                
(IQR, 0.5-2.2)
 
0.8                                
(IQR, 0.6-1.4)
p value    
(Pre-ART         






p value   
(Pre-ART        





INFã CD4% = CD4 T Cells expressing INFã after stimulation 
with PPD 
INFã CD8% = CD8 T Cells expressing INFã after stimulation 
with PPD 
IQR = Interquartile range 
DISCUSSION
A statistically significant increase of CD4 T cell 
percentages was demonstrated after starting 
antiretroviral therapy. After 6 months of ART, the 
CD4 T cell percentage increased from 9.7% to 
25.0%.  These findings are consistent  with a 
11Belgium study by Hainaut et al  on children, which 
found that there was a significant increase in CD4 T 
cell counts after ART  from 294 cells /ml to 459 cells 
/ml  after 3 months and  619 cells / ml after 6 months. 
This clearly demonstrated general immune 
reconstitution after commencement of ART. On the 
other hand, there was a decrease in CD8 T cell 
percentage after starting ART. Before ART, the 
median CD8 T cell percentage was 42.8%, but after 6 
months of ART, it decreased to 36.5%. A study by 
Wherry and Ahmed suggested that during viral 
infection CD8 T cells undergo an expansion phase, 
12leading to the generation of effector CD8 T cells . 
The expansion phase is followed by a death phase, 
when 90 - 95% of the effector T cells die. This may 
explain the high levels of CD8 T cells before ART 
followed by the decline after ART initiation.
Focusing on T cell subsets, there was an increase in 
both naïve CD4 and CD8 T cells after starting ART. 
Although naïve CD4 T cells did not show a 
statistically significant increase, naïve CD8 T cells 
increased significantly after 6 months. This agrees 
13with a study by Franco et al  which showed an 
increase in both naïve CD4 and CD8 T cells after 
ART. Partly, this may explain the increase in both 
total CD4 T cells and total CD8 T cells. 
Our results show that there were more activated CD4 
T cells and CD8 T cells before starting ART 
compared to after 3 and 6 months of ART. This result 
14,15
agrees with a study by Hainaut et al  that found a 
decrease in activated CD8 T cells after three months 
of ART in HIV infected children. High levels of 
activated T cells before commencement of ART may 
be attributed to high viral load. After ART, there is a 
decrease in viral load resulting in the reduction of 
16
activation of T cells . 
Before starting ART, there were more effector 
memory T cells as compared to central memory T 
cells. A significant increase was observed in the 
central memory CD4 T cell percentage after 6 
months of ART. On the other hand, effector memory 
CD4 T-cells decreased over the same period of time. 
The picture is similar when we compare central 
memory CD8 T cells to effector memory CD8 T 
cells. Central memory CD8 T–cells increase while 
effector memory CD8 cells decrease over time. This 
is consistent with the literature, as central memory T 
cells are longer lived and confer long-term memory 
while effector memory T cells can rapidly mature 
into effector T cells and secrete cytokines such as 
13,17IFNã and IL4 early after restimulation . A study by 
17Resino et al  found that elevated percentages of total 
CD8 T –cells were associated with increased 
memory CD4 T-cells. If this is true, then one may 
conclude that most of these memory CD4 T-cells are 
actually effector memory CD4 T-cells.
Focusing on antimycobacterial-specific immune 
response, CD4 T cells that expressed IFNã in 
response to stimulation with PPD decreased 
significantly after 3 months of ART. This agrees with 
18
a study by Wilkinson et al  where IFNã responses 
were found to decrease after 11 months of ART in 
220
HIV infected adults. This may be explained by a 
19study by Sutherland et al , which found that the 
proportion of CD4 T cells producing IFNã in 
response to TB antigens was higher in HIV-infected 
patients with lower CD4 counts but the ability to 
produce higher IFNã levels relied on CD8 T cells. 
However, our study found that after 6 months of 
ART, the percentage of CD4 T cells producing IFNã 
went back to pre ART levels. To the author's 
knowledge, no study has ever documented this 
phenomenon, except it can be speculated that this 
may be due to the increase by CD4 T cells 
percentage after ART and the significant increase in 
the percentage of central memory CD8 T cells may 
play a role as well. For CD8 T cells, there was no 
statistically significant difference by IFNã-
producing cells in response to stimulation to PPD 
after ART. This may reflect unmeasured factors in 
these children or the time period was too short to 
measure substantial changes in CD8 T cells 
expressing IFNã. It should be noted that although 
IFNã is crucial in the protective immune response to 
TB, it is not enough on its own for an effective 
19immune response .
CONCLUSION
Children in this study responded well to ART as 
indicated by increases in CD4 T cell percentages 
after 6 months of ART. This demonstrated that ART 
has a positive impact since CD4 T cells are central to 
an effective immune response against HIV and this 
in turn will reduce the risk of tuberculosis in HIV 
infected children. Overall, there was no significant 
difference in T cells expressing IFNã upon 
stimulation with PPD after 6 months of ART, 
however the response before ART seem to be 
primarily driven by effector memory T cells as 
evidenced by their high percentage while that after 
ART by central memory T cells. This suggests that in 
the context of improved TB antigen specific T cell 
responses, central memory T cells are the primary 
cells in restoring immune response. These findings 
have important implications in vaccine development 
strategies for TB in HIV infected children. 
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